Abstract:Persons with germline variants in the tumor suppressor gene phosphatase and tensin homolog, PTEN , are molecularly diagnosed with PTEN hamartoma tumor syndrome (PHTS). PHTS confers high risks of specific malignancies, and up to 23% of the patients are diagnosed with autism spectrum disorder (ASD) and/or developmental delay (DD). The accurate prediction of these two seemingly disparate phenotypes (cancer vs . ASD/DD) for PHTS at the individual level remains elusive despite the available statistical prevalence of specific phenotypes of the syndrome at the population level. The pleiotropy of the syndrome may, in part, be due to the alterations of the key multi-functions of PTEN. Maintenance of genome integrity is one of the key biological functions of PTEN, but no integrative studies have been conducted to quantify the DNA damage response (DDR) in individuals with PHTS and to relate to phenotypes and genotypes. In this study, we used 43 PHTS patient-derived lymphoblastoid cell lines (LCLs) to investigate the associations between DDR and PTEN genotypes and/or clinical phenotypes ASD/DD vs . cancer. The dynamics of DDR of γ-irradiated LCLs were analyzed using the exponential decay mathematical model to fit temporal changes in γH2AX levels which report the degree of DNA damage. We found that PTEN nonsense variants are associated with less efficient DNA damage repair ability resulting in higher DNA damage levels at 24 hours after irradiation compared to PTEN missense variants. Regarding PHTS phenotypes, LCLs from PHTS individuals with ASD/DD showed faster DNA damage repairing rate than those from patients without ASD/DD or cancer. We also applied the reaction-diffusion partial differential equation (PDE) mathematical model, a tumor cell growth model with a DNA damage term, to accurately describe the DDR process in the LCLs. For each LCL, we can derive parameters of the PDE. Then we averaged the numerical results by PHTS phenotypes. By performing simple subtraction of two subgroup average results, we found that PHTS-ASD/DD is associated with higher live cell density at lower DNA damage level but lower cell density level at higher DNA damage level compared to LCLs from individuals with PHTS-cancer and PHTS-neither. PTEN is a shared risk gene for both cancer and autism spectrum disorder (ASD) and/or developmental delay (DD). Accurate prediction of the clinical phenotypes of each PTEN hamartoma tumor syndrome (PHTS) individual is still not feasible, though population-level risks of ASD/DD and specific component cancers, including breast cancer and thyroid cancer, have been estimated within PHTS cohorts. In this study we provide insights that PHTS-ASD/DD is associated with faster DNA damage repair rate (half-life of phosphorylated H2A histone family member X, γH2AX, signal over time) and LCLs derived from individuals with PHTS-cancer are related with susceptibility to γ irradiation. PHTS-ASD/DD also showed a higher live cell density when DNA damage was at a low level, and lower live cell density at high DNA damage levels compared to the other PHTS phenotypes. Finally, we provide an innovative way to describe DNA damage response (DDR) in a quantitative and integrative fashion, which is applicable to any type of cells.

Functional analysis of PTEN variants of unknown significance from PHTS patients unveils complex patterns of PTEN biological activity in disease

WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition

Abstract 6233: Characterizing variants of uncertain significance in the tumor suppressor gene known as phosphatase and tensin homolog (PTEN)

PTEN hamartoma tumor syndrome: Clinical and genetic characterization in pediatric patients

Classification of PTEN germline non-truncating variants: a new approach to interpretation

Mutation-Positive and Mutation-Negative Patients with Cowden and Bannayan-Riley-Ruvalcaba Syndromes Associated with Distinct 10q Haplotypes

PTEN: one gene, many syndromes

PTEN Hamartoma Tumor Syndrome: A Clinical Overview

The Genomic Landscape of Benign and Malignant Thyroid Tumors from Individuals Carrying Germline PTEN Variants Is Distinct from Sporadic Thyroid Cancers

Diagnosis of PTEN mosaicism: the relevance of additional tumor DNA sequencing. A case report and review of the literature

The complexity of PTEN: mutation, marker and potential target for therapeutic intervention

Regulation of the tumor suppressor PTEN by natural anticancer compounds

Clinical, histological and receptor profiles of invasive breast cancer and ductal carcinoma in situ in females with germline pathogenic variants in PTEN and implications for germline testing

Cerebellar phenotypes in germline PTEN mutation carriers

Exploring the neurological features of individuals with germline PTEN variants: A multicenter study

Targeting PTEN Regulation by Post Translational Modifications

Classification of PTEN missense VUS through exascale simulations

Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives

Quantitative evaluation of DNA damage repair dynamics to elucidate predictors of autism vs . cancer in individuals with germline PTEN variants

Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers

Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer